65.15 +0.57 (0.88%)
After hours: 5:47PM EST
Arrowhead submitted an IND to the U.S. Food and Drug Administration for ARO-APOC3, an RNAi therapeutic for hypertriglyceridemia
A look at the shareholders of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that used to be publicly owned tend to have lower insider ownership.
ARWR earnings call for the period ending December 31, 2020.